Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CiPA Phase 1 ECG Biomarker Study
NCT03070470Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Mar 2017
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ranolazine, verapamil, lopinavir, ritonavir, chloroquine and 2 more in long QT syndrome (LQTS), sponsored by Food and Drug Administration. Started Mar 2017; status: completed.
02
Drugs
ranolazineverapamillopinavirritonavirchloroquine
03
Conditions
long QT syndrome (LQTS)
Beyond the preview
Go deeper on NCT03070470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070470.